Read Also: AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients Biopharmaceutical giant AbbVie Inc.
(NYSE:ABBV) announced Monday that it has agreed to acquire Apogee Therapeutics Inc.
(NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion.
The deal strengthens its immunology portfolio and accelerates AbbVie's expansion into respiratory diseases through a pipeline of clinical-stage therapies targeting atopic dermatitis and asthma.
AbbVie will pay $135.11 per share in cash for all outstanding Apogee shares.
